Table 4.
Univariate and multivariate cox analysis results of the prognostic factors LC patients.
| Univariate cox analysis | Multivariate cox analysis | |||
|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Age | ||||
| <50 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 50-59 | 1.29(1.22-1.37) | <0.001 | 1.36(1.28-1.44) | <0.001 |
| 60-69 | 9(1.31-1.47) | <0.001 | 3(1.54-1.73) | <0.001 |
| 70-79 | 61(1.52-1.70) | <0.001 | 2.15(2.03-2.28) | <0.001 |
| >=80 | 2.25(2.12-2.39) | <0.001 | 3.46(3.27-3.67) | <0.001 |
| Race | ||||
| Black | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| White | 0.98 (0.94-1.01) | 0.1910 | 0.94(0.90-0.97) | <0.001 |
| Other | 0.91 (0.87-0.95) | <0.001 | 0.77(0.74-0.81) | <0.001 |
| Unknown | 0. 35(0.24-0.50) | <0.001 | 0.45(0.31-0.65) | <0.001 |
| Sex | ||||
| Female | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Male | 1.3(1.27-1.33) | <0.001 | 1.23(1.21-1.26) | <0.001 |
| Pathology | ||||
| AD | 1 (reference) | 1(reference) | 1 (reference) | 1 (reference) |
| SCC | (1.05-1.11) | <0.001 | 1.13(1.10-1.16) | <0.001 |
| LCC | (1.11-1.31) | <0.001 | 1.29(1.19-1.41 | <0.001 |
| NSCLC-NOS | (1.48-1.60) | <0.001 | 38(1.33-1.44) | <0.001 |
| SCLC | 1.72(1.67-1.77) | <0.001 | 1.22(1.18-1.26) | <0.001 |
| Other | 0.75(0.73-0.77) | <0.001 | 1.02(0.99-1.06) | 0.1268 |
| Site of the primary tumor | ||||
| LLL | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| LMB | 65 (1.53-1.78) | <0.001 | 1.18(1.10-1.28) | <0.001 |
| LUL | 1.04 (1.00-1.07) | 0.0551 | 0.99(0.95-1.03) | 0.5721 |
| RLL | 1.04(1.00-1.08) | 0.0580 | 1.03(0.99-1.07) | 0.1550 |
| RMB | 1.88(1.76-2.01) | <0.001 | 1.31(1.22-1.40) | <0.001 |
| RML | 0.90(0.86-0.96) | <0.001 | 0.94(0.89-0.99) | 0.0268 |
| RUL | 1.03(0.99-1.07) | 0.1060 | 0.99(0.96-1.03) | 0.6923 |
| Other | 1.85(1.77-1.93) | <0.001 | 1.31(1.26-1.37) | <0.001 |
| Separate tumor nodule | ||||
| NO | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| YES | 1.74(1.70-1.78) | <0.001 | 0.94(0.92-0.97) | <0.001 |
| other | 97(1.88-2.07) | <0.001 | 1.33(1.26-1.39) | <0.001 |
| T stage | ||||
| T1 | 1 (reference) | 1 (reference) | (reference) | 1 (reference) |
| T2 | 1.80(1.75-1.86) | <0.001 | 1.45(1.40-1.49) | <0.001 |
| T3 | 2.56(2.49-2.65) | <0.001 | 1.86(1.79-1.93) | <0.001 |
| T4 | 18(3.08-3.28) | <0.001 | 1.99(1.92-2.06) | <0.001 |
| TO | 53(2.24-2.86) | <0.001 | 1.14(1.01-1.29) | 0.0406 |
| N stage | ||||
| NO | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| N1 | 66(1.60-1.72) | <0.001 | 41(1.36-1.46) | <0.001 |
| N2 | 57(2.51-2.64) | <0.001 | 1.88(1.83-1.93) | <0.001 |
| N3 | 2.90(2.81-2.99) | <0.001 | 1.99(1.93-2.06) | <0.001 |
| Number of metastases | 1.87(1.85-1.89) | <0.001 | 1.67(1.64-1.69) | <0.001 |